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1. Introduction 
A non-covalent interaction is a kind of chemical bond, typically between macromolecules, 
that involves dispersed variations of electromagnetic interactions (Alberts et al. 1994; 
Connors & Mecozzi 2010). Non-covalent interactions are individually weak as compared 
with covalent bonds, but their net strength is higher than the sum of that of the individual 
interactions. There are few drugs that bind irreversibly to their targets, in pharmacology, 
most drugs establish non-covalent interactions with their target molecules (usually 
proteins). 
From a chemical point of view, the affinity constant (Ka) is a very useful measurement for 
the study of binding reactions as it provides much information about the mechanism. In 
many cases some chemical or physical properties of ligand or target change with the 
interaction between them, these changes might help to measure binding constants. It is 
important to establish the stoichiometry of the complex to be sure that the constants are 
accurately calculated. From the affinity constants measured it is possible to calculate the 
standard thermodynamic quantities for the binding reaction: free-energy (ΔG), enthalpy 
(ΔH) and entropy (ΔS).  
Our group has already demonstrated that, in some cases, binding affinity measurements are 
very helpful for the optimization of ligand binding as it can be determined the contribution 
of every single chemical modification of the ligand to the binding affinity (Buey et al. 2004; 
Matesanz et al. 2008) 
One of the objectives of drug development is the search of new or modified compounds 
with improved properties such as better potency, higher selectivity, better pharmacokinetics 
or superior drug resistance profiles. An important goal in this objective is the optimization 
of drugs binding affinity towards their targets, as binding affinity is directly related to 
potency (Ruben et al. 2006). Moreover, it has been shown that extremely high affinity drugs 
reflect as well changes in other properties like selectivity (Ohtaka et al. 2004; Ohtaka & Freire 
2005) or resistance overcoming ability (Matesanz et al. 2008).  
Examples of the importance of ligand affinity in drug optimization can be observed in the 
development of HIV-1 protease inhibitors and statins (cholesterol lowering drugs) over the 
years as remarked in (Freire 2008). 
In this chapter we will study the nature of non-covalent interations and the concept of 
binding constant for these interactions. Examples of methodologies to measure binding 
constants of small ligands to macromolecules will be introduced and we will emphasize the 
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need to determine the stoichiometry of the studied system to calculate accurately the 
constants. Once the thermodynamic concepts were introduced, we will show the use of 
these kind of studies for the optimization of drug binding to its target. We will detail the 
role of single chemical modifications in the molecule of study to modulate its binding 
affinity, and the way to quantify these changes. We will finally further discuss how the 
selection of the best sustituents can result in the optimization of binding.  
2. Non-covalent interactions 
Non-covalent interactions are chemical bonds that do not involve sharing of electron pairs 
between orbitals of different atoms, there are no orbital overlapping in these interactions 
which have an electrostatic nature and are not highly directional. Covalent bonds are 
generally shorter than 2Å while the non-covalent ones are within the range of several 
angstroms. Another difference between these two types of bonds is the energy released in its 
formation, non-covalent interactions are weaker, with energies below 40 kJ/mol whereas 
covalent bonds energies range 80-800 kJ/mol.  
These weak interactions have important roles in the binding of macromolecules with each 
other and with other molecules in the cell, in the mainteinance of the three dimensional 
structure of large macromolecules such as proteins or nucleic acids (e.g. DNA double helix) 
and they are the forces found in the majority of the drug-proteins interactions in 
pharmacology.  
2.1 Types of non-covalent interactions 
There are four commonly mentioned fundamental non-covalent interaction types including 
ionic interactions, hydrogen bonds, hydrophobic interactions and van der Waals forces 
(dispersion attractions, dipole-dipole and dipole-induced dipole interactions). All these weak 
interactions must work together to have significant effects. Their combined bond effect is 
greater than the sum of the individual ones. The free energy of multiple bonds between two 
molecules is different than the sum of the enthalpies of each bond due to entropic effects. 
2.1.1 Ionic interactions 
Ionic bonds result from the electrostatic attraction between two ionized groups of opposite 
charge such as carboxyl (-COO-) and amino (-NH3+). These ionic interactions are directly 
proportional to the product of the interacting charges and inversely proportional to the 
dielectric constant of the medium and the distance separating the charges. This relationship 
is defined by Coulomb's law:   
 E =
kq1q2
Dr  
(1) 
where E is the energy, q1 and q2 are the charges of two atoms, r is the distance between 
them, D is the dielectric constant, and k is a proportionality constant. A charged group on a 
molecule can attract an oppositely charged group from another molecule. By contract, an 
attractive interaction has a negative energy. The dielectric constant is important for the 
medium. In water, these bonds are very weak as the dielectric constant is much higher 
(D=80) than in vacuum (D=1). As an example, the electrostatic interaction between two 
atoms bearing single opposite charges separated by 3 Å in water has an energy of 5.9 kJ/mol 
(k=1389 kJ/mol). 
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2.1.2 Van der Waals forces 
Van der Waals forces are short range attractive forces between chemical groups in contact. 
The forces are caused by slight charge displacements. The distribution of electronic charge 
around an atom changes with time. At any moment, the charge distribution is not perfectly 
symmetric. This transient asymmetry in the electronic charge around an atom induces a 
complementary asymmetry in the electron distribution around its neighboring atoms. These 
induced dipole effects give rise to the so called van der Waals interactions, also known as 
dispersion forces. The attraction between two atoms increases as they come closer to each 
other, until they are separated by the so called van der Waals contact distance. At a shorter 
distance, very strong repulsive forces become dominant because the outer electron clouds 
overlap.  The van der Waals radius of an atom is defined where the net force between two 
atoms is zero. The van der Waals potential is then best described as a balance between 
attraction and repulsion.  
Van der Waals forces are non-directional. Energies associated with them are quite small; 
typical interactions contribute from 2 to 4 kJ/mol per atom pair. However, when the 
surfaces of two large molecules come together, a large number of atoms are in van der 
Waals contact, and the net effect, summed over many atom pairs, can be substantial.  
2.1.3 Hydrogen bonds 
A hydrogen bond is an interaction between a proton donor group (a hydrogen atom 
covalently bound to an electronegative atom -e.g. F, O, N, S-) and a proton acceptor atom 
(another electronegative atom). It is a very important interaction responsible for the 
structure and properties of water, as well as the structure and properties of biological 
macromolecules (e.g. hydrogen bonds are responsible of specific base-pair formation in the 
DNA double helix). 
Hydrogen bonds are fundamentally electrostatic interactions. The relatively electronegative 
atom to which the hydrogen atom is covalently bonded pulls electron density away from the 
hydrogen atom so that it develops a partial positive charge (δ+). Thus, it can interact with an 
atom having a partial negative charge (δ-) through an electrostatic interaction. However, this 
interaction is more than just an ionic or dipole-dipole interaction between the donor and the 
acceptor groups. Here, the distance between the hydrogen and acceptor atoms is less than 
the sum of their respective van der Waals radii.  
Hydrogen bonds are directional toward the electronegative atom. The strongest hydrogen 
bonds have a tendency to be approximately straight, such that the proton donor group, the 
hydrogen atom, and the acceptor atom lie along a straight line, with significant weakening 
of the interaction if they are not colinear. They are somewhat longer than are covalent 
bonds. Hydrogen bonds are constantly being made and remade. Their half-life is about 10 
seconds. These bonds have only 5% or so of the strength of covalent bonds. They have 
energies of 5-15 kJ/mol compared with approximately 420 kJ/mol for a carbon-hydrogen 
covalent bond. However, when many hydrogen bonds can form between two molecules (or 
parts of the same molecule), the resulting union can be sufficiently strong as to be quite 
stable. Examples of multiple hydrogen bonds are widely found in biological systems, they 
hold secondary structures of polypeptides, help in binding of enzymes to their substrate or 
antibodies to their antigen, help also transcription factors bind to each other or to DNA. 
2.1.4 Hydrophobic interactions 
Hydrophobic interactions result when non-polar molecules are in a polar solvent (e.g. 
water). The non-polar molecules group together to exclude water so that they minimize the 
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surface area in contact with the polar solvent. Unlike the non-covalent interactions 
mentioned above, which are pairwise interactions between atoms or parts of molecules, the 
nature of the hydrophobic interaction is very different. It involves a considerable number of 
(water) molecules, and does not arise from a direct force between the non-polar molecules. 
Nonpolar molecules are not good acceptors of hydrogen bonds. When a non-polar molecule 
is placed in water, the hydrogen bonding network of water is disrupted. Water molecules 
must reorganize around the solute and make a kind of cage, similar to the structure of water 
in ice, in order to gain back the broken hydrogen bonds. This reorganization results in a 
considerable loss in the configurational entropy of water and therefore, in an increase in the 
free energy. If there are more than one such non-polar molecules, the configuration in which 
they are clustered together is preferred because now the hydrogen bonding network of 
water is disrupted in just one (albeit bigger) pocket, rather than in several small pockets. 
Therefore, the entropy of water is larger when the non-polar molecules are clustered 
together, leading to a decrease in the free energy. 
Hydrophobic interactions have strengths comparable in energy to hydrogen bonds. 
3. Binding constants 
Most drugs have a non-covalent binding to their targets, thus these interactions are of 
great importance for our studies. Measurements of equilibrium constants, their 
dependence with temperature, the determination of stoichiometry, provide main 
information on the mechanism of the chemical process involved. The basic process can be 
taken out of the association of ligand (or ligands) to its target. The binding reaction can be 
writen as follows:  
 mP + nL ↔ PmLn  (2) 
Regardless of mechanism, every reversible reaction reaches an equilibrium distribution of 
reactants and products. At some point the rates of the opposing reactions (association and 
dissociation in our case) become equal and there would no longer be any change in the 
concentration of the molecules implied.  
 vass	=	kass[P]m[L]n (3) 
 vdiss= kdiss[PmLn] (4)	
Under these conditions (vass = vdiss): 
 kass
kdiss
= [PmLn]
[P]m[L]n
= Ka (5) 
that will be the equilibrium association constant assuming that activities are equal to 
concentrations.  
In this section we will discuss the cases for one single site in the target, multiple sites with 
same affinities and multiple sites with different affinities. 
3.1 One-site binding 
In the simplest case, where there is only one site per target molecule, n and m are 1. It is 
possible to define the fraction of occupied binding sites (υ) as: 
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 υ = Lbound
Ptotal
= [PL]
[PL] + [P] 
(6) 
Determining υ is often easy in spectrophotometric manipulation as will be discussed later. 
Given υ, equation 5 can then be solved for [PL] and the answer substituted into equation 6 
to obtain the quantitative 1:1 stoichiometric model: 
 υ = Ka[L]
1	+	Ka[L] (7) 
This equation is the 1:1 binding isotherm also known as the Langmuir isotherm or the 
“direct” plot. Its functional form is a rectangular hyperbola whose midpoint will yield Ka. 
Chemical interpretation of 1:1 binding is that the target P has a single “binding site”, as has 
the ligand L; and when the complex PL forms, no further sites are available for the binding 
of any additional ligand. To test the 1:1 stoichoimetry equation 7 may be rearrange into a 
linear plotting form. Since υ is the bound fraction, then 1-υ is the free one: (1- υ) = 
1/(1+Ka[L]). Thus υ/(1- υ) = Ka[L], and: 
  log 	 υ
1- υ= log  [L]  + log 	Ka (8) 
This log-log plot should be linear with a slope of one if the stoichoimetry is really 1:1. This is 
called a Hill plot. Equation 7 can be also rearranged to three different non-logarithmic linear 
plotting forms. Taking simply the reciprocal of the equation yields the double-reciprocal 
plot (used by plotting 1/υ against 1/[L]): 
 1υ=
1
Ka[L]
 + 1 (9) 
In spectroscopic studies this plot is commonly known as the Benesi-Hildebrand plot (Benesi 
& Hildebrand 1949). 
Another plot is that of [L]/υ against [L] which is expected to be linear: 
 [L]υ = [L] + 
1
Ka
 (10) 
And the third plotting of υ/[L] agains υ, sometimes called Scatchard plot (Scatchard 1949): 
 υ
[L]
= υKa + Ka (11) 
Linearity in all of these plots is a necessary condition if the 1:1 model is valid; and from the 
parameters of equations Ka can be evaluated. Usually υ is not measured directly but rather 
some experimental quantity related to it, so that the interpretation of the plots depends on 
the particular experimental methodology.  
3.2 Multi-site binding 
Most biological systems tend to have more than one binding site, that is the case of many 
systems of small molecules binding to proteins. In these cases we may consider that n 
ligands may bind to a single target molecule. The average number of ligand molecules 
bound per target molecule (b) is defined as: 
 b = Ltotal –	[L]
Ptotal
 (12) 
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Assuming that all n binding sites in the target molecule are identical and independent, it is 
possible to establish: 
 b =  nk[L]
1 + k[L] 
(13) 
where k is the constant for binding to a single site. According to this equation this system 
follows the hyperbolic function characteristic for the one-site binding model. To define the 
model n and k can be evaluated from a Scatchard plot. The affinity constant k is an average 
over all binding sites, it is in fact constant if all sites are truly identical and independent. A 
stepwise binding constant (Kst) can be defined which would vary statistically depending on 
the number of target sites previously occupied. It means that for a target with n sites will be 
much easier for the first ligand added to find a binding site than it will be for each succesive 
ligand added. The first ligand would have n sites to choose while the nth one would have 
just one site to bind. The stepwise binding constant can be defined as: 
 Kst=
number of free target sites
number of bound sites
k = n – b + 1
b
k (14) 
It is interesting to notice that a deviation from linearity in the Scatchard plot (and to a lesser 
extent in the Benesi-Hildebrand) gives information on the nature of binding sites. A curved 
plot denotes that the binding sites are not identical and independent. 
3.3 Allosteric interactions 
Another common situation in biological systems is the cooperative effect, in that case several 
identical but dependent binding sites are found in the target molecule. It is important to 
define the effect of the binding of succesive ligands to the target to describe the system. An 
useful model for that issue is the Hill plot (Hill 1910). In this case the number of ligands 
bound per target molecule will be (take into account that the situation in this system for 
equation 2 is m=1 and n≠1): 
 b = n[PLn]
[PLn] + [P]
 (15) 
if equation 5 is solved for [PLn] and substitute into equation 15, then: 
 b = nKa[L]
n
Ka[L]
n + 1 
(16) 
This expression can be rewritten as: 
 b
n - b
= Ka[L]
n
 (17) 
Note that the fraction of sites bound, υ (see equation 6), is the number of sites occupied, b, 
divided by the number of sites available, n. Then equation 17 becomes: 
 υ
1 - υ= Ka[L]
n
 (18) 
Equation 18 is known as the Hill equation. From the Hill equation we arrive at the Hill plot 
by taking logarithms at both sides: 
 log 	 υ
1 - υ= nH log 	[L]  + log 	Ka (19) 
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Plotting log(υ/(1-υ)) against log[L] will yield a straight line with slope nH (called the Hill 
coefficient). The Hill coefficient is a qualitative measure of the degree of cooperativity and it 
is experimentally less than the actual number of binding sites in the target molecule. When 
nH > 1, the system is said to be positively cooperative, while if nH < 1, it is said to be anti-
cooperative. Positively cooperative binding means that once the first ligand is bound to its 
target molecule the affinity for the next ligand increases, on the other hand the affinity for 
subsequent ligand binding decreases in negatively cooperative (anti-cooperative) systems. 
In the case of nH = 1 a non-cooperative binding occurs, here ligand affinity is independent of 
whether another ligand is already bound or not. 
Since equation 19 assumes that nH = n, it does not described exactly the real situation. When 
a Hill plot is constructed over a wide range of ligand concentrations, the continuity of the 
plot is broken at the extremes concentrations. In fact, the slope at either end is 
approximately one. This phenomenon can be easily explained: when ligand concentration is 
either very low or very high, cooperativity does not exist. For low concentrations it is more 
probable for individual ligands to find a target molecule “empty” rather than to occupy 
succesive sites on a pre-bound molecule, thus single-binding is happening in this situation. 
At the other extreme, for high concentrations, every binding-site in the target molecule but 
one will be filled, thus we find again single-binding situation. The larger the number of sites 
in a single target molecule is, the wider range of concentrations the Hill plot will show 
cooperativity. 
4. Determination of binding constants 
As discuss above the binding constant provides important and interesting information 
about the system studied. We will present a few of the multiple experimental posibilities to 
measure this constant (further information could be found in the literature (Johnson et al. 
1960; Connors 1987; Hirose 2001; Connors&Mecozzi 2010; Pollard 2010)). It is essencial to 
keep in mind some crucial details to be sure to calculate the constants properly: it is 
important to control the temperature, to be sure that the system has reached the equilibrium 
and to use the correct equilibrium model. One common mistake that should be avoid is 
confuse the total and free concentrations in the equilibrium expression. 
Different techniques are commonly used to study the binding of ligands to their targets. 
These techniques can be classified as calorimetry, spectroscopy and hydrodynamic methods. 
Hydrodynamic techniques are tipically separation methodologies such as different 
chromatographies, ultracentrifugation or equilibrium dialysis with which free ligand, free 
target and complex are physically separated from each other at equilibrium, thus 
concentrations of each can be measured. Spectroscopic methodologies include optical 
spectroscopy (e.g. absorbance, fluorescence), nuclear magnetic resonance or surface plasmon 
resonance. Calorimetry includes isothermal titration and differential scanning. Calorimetry 
and spectroscopy methods allow accurately determination of thermodynamics and kinetics 
of the binding, as well as can give information about the structure of binding sites. 
Once the bound (or free) ligand concentration is measured, the binding proportion can be 
calculated. Other thermodynamic parameters can be calculated by varying ligand or target 
concentrations or the temperature of the system. 
4.1 Determination of stoichiometry. Continuous variation method. 
Since correct reaction stoichiometry is crucial for correct binding constant determination we 
will study how can it be evaluated. There are different methods of calculating the 
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stoichoimetry: continuous variation method, slope ratio method, mole ratio method, being 
the first one, the continuous variation method the most popular. In order to determine the 
stoichiometry by this method the concentration of the produced complex (or any property 
proportional to it) is plotted versus the mole fraction ligand ([L]total/([P]total+[L]total)) over a 
number of tritation steps where the sum of  [P]total and [L]total is kept constant (α) changing 
[L]total from 0 to α. The maxima of this plot (known as Job’s plot, (Job 1928; Ingham 1975)) 
indicates the stoichiometry of the binding reaction: 1:1 is indicated by a maximum at 0.5 
since this value corresponds to n/(n+m). For the understanding of the theoretical 
background of the method, it is important to remember equations 2 and 5; notice that: 
 [P]total=	[P]	+ m[PmLn] (20) 
 [L]total=	[L] +	n[PmLn] (21) 
 α = [L]total + [P]total (22) 
 x =
[L]total
[P]total + [L]total
 (23) 
 y =	[PmLn] (24) 
Substitution of [P]total and [L]total by the functions of α and x from equation 23 and 24 yields: 
 [P]total= α - αx (25) 
 [L]total= αx (26) 
from equations 2, 5, 20, 21, 24, 25, 26: 
 y = Ka(α - my - αx)m(αx - ny)n (27) 
Equation 27 is differentiated, and the dy/dx substituted by zero to obtain the x-coordinate at 
the maximum: 
 x = n
n	+	m (28) 
This equation shows the correlation between stoichiometry and the x-coordinate at the 
maximum in Job’s plot. That’s why a maximum at x = 0.5 means a 1:1 stoichiometry (n = m 
= 1). In the case of 1:2 the maximum would be at x = 1/3.  
4.2 Calorimetry 
Isothermal titration calorimetry (ITC) is a useful tool for the characterization of 
thermodynamics and kinetics of ligands binding to macromolecules. With this method the 
rate of heat flow induced by the change in the composition of the target solution by tritation 
of a ligand (or vice versa) is measured. This heat is proportional to the total amount of 
binding. Since the technique measures heat directly, it allows simultaneous determination of 
the stoichiometry (n), the binding constant (Ka) and the enthalpy (ΔH0) of binding. The free 
energy (ΔG0) and the entropy (ΔS0) are easily calculated from ΔH0 and Ka. Note that the 
binding constant is related to the free energy by: 
 ∆G 0= -RT ln Ka (29) 
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where R is the gas constant and T the absolute temperature. The free energy can be dissected 
into enthalpic and entropic components by: 
 ∆G 0= ∆H0-	T∆S0 (30) 
On the other hand, the heat capacity (ΔCp –p subscript indicates that the system is at 
constant pressure-) of a reaction predicts the change of ΔH0 and ΔS0 with temperature and 
can be expressed as: 
 ∆Cp= ∆H
0
T2 - ∆H0T1
T2- T1
 (31) 
or 
 ∆Cp= ���T2 - ���T1
ln  
T2
T1
 (32) 
In an ITC experiment a constant temperature is set, a precise amount of ligand is added to a 
known target molecule concentration and the heat difference is measured between reference 
and sample cells. To eliminate heats of mixing effects, the ligand and target as well as the 
reference cell contain identical buffer composition. Subsequent injections of ligand are done 
until no further heat of binding is observed (all sites are then bound with ligand molecules). 
The remaining heat generated now comes from dilution of ligand into the target solution. 
Data should be corrected for the heat of dilution. The heat of binding calculated for every 
injection is plotted versus the molar ratio of ligand to protein. Ka is related to the curve 
shape and binding capacity (n) determined from the ratio of ligand to target at the 
equivalence point of the curve. Data must be fitted to a binding model. The type of binding 
must be known from other experimental techniques. Here, we will study the simplest model 
with a single site. Equations 6 and 7 can be rearranged to find the following relation 
between υ and Ka: 
 Ka=
υ
(1-υ)[L] (33) 
Total ligand concentration is known and can be represented as (remember that we are 
assuming m=n=1): 
 [L]total= [L] + υ[P]total (34) 
Combining equations 33 and 34 gives: 
 υ2- �[L]total
[P]total
+ 1
Ka[P]total
+	1� υ + [L]total
[P]total
= 0 (35) 
Solving for υ:  
 υ = 1
2
 ��[L]total
[P]total
+ 1
Ka[P]total
+ 1� -��[L]total
[P]total
+ 1
Ka[P]total
+ 1�2 - 4 [L]total
[P]total
� (36) 
The total heat content (Q) in the sample cell at volume (V) can be defined as: 
 Q = [PL]∆H0V = υ[P]total∆H0V   (37) 
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where ΔH0 is the heat of binding of the ligand to its target. Substituing equation 36 into 37 
yields: 
 Q = 
[P]total∆H0V
2
��[L]total
[P]total
+ 1
Ka[P]total
+ 1�  - ��[L]total
[P]total
+ 1
Ka[P]total
+ 1�2  - 4 [L]total
[P]total
�   (38) 
Therefore Q is a function of Ka and ΔH0 (and n, but here we considered it as 1 for simplicity) 
since [P]total, [L]total and V are known for each experiment.  
4.3 Optical spectroscopy 
The goal to be able to determine binding affinity is to measure the equilibrium concentration 
of the species implied over a range of concentrations of one of the reactants (P or L). 
Measuring one of them should be sufficient as total concentrations are known and therefore 
the others can be calculated by difference from total concentrations and measured 
equilibrium concentration of one of the species. Plotting the concentration of the complex 
(PL) against the free concentration of the varying reactant, the binding constant could be 
calculated.  
4.3.1 Absorbance 
As an example a 1:1 stoichiometry model will be shown, wherein the Lambert-Beer law is 
obeyed by all the reactants implied. To use this technique we should ensured that the 
complex (PL) has a significantly different absorption spectrum than the target molecule (P) 
and a wavelenght at which both molar extinction coefficients are different should be 
selected. At these conditions the absorbance of the target molecule in the absence of ligand 
will be: 
 Abs0= εP	l [P]total (39) 
If ligand is added to a fixed total target concentration, the absorbance of the mix can be 
written as: 
 Absmix= εP l [P] + εL l [L] + εPL l [PL] (40) 
Since [P]total = [P] + [PL] and [L]total = [L] + [PL], equation 40 can be rewritten as: 
 Absmix= εP l [P]total+ εL l [L]total+ ∆ε l [PL] (41) 
where Δε = εPL-εP-εL. If the blank solution against which samples are measured contains 
[L]total, then the observed absorbance would be: 
 Absobs= εP l [P]total+ Δε l [PL] (42) 
Substracting equation 39 from 42 and incorporating Ka (equation 5): 
 ∆Abs = Ka ∆ε l [P] [L] (43) 
[P]total can be written as [P]total = [P](1+Ka[L]) which included in equation 43 yields: 
 ΔAbs
l
=
[P]total Ka ∆ε [L]�	�	 Ka	[L]  (44) 
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which is the direct plot expressed in terms of spectrophotometric observation. Note that the 
dependence of ΔAbs/l on [L] is the same as the one shown in equation 7.  
The free ligand concentration is actually unknown. The known concentrations are [P]total to 
which a known [L]total is added. In a similar way as shown above for [P]total, [L]total can be 
written as: 
 [L]total= [L] 
[P]total Ka [L]
1 + Ka [L]
 (45) 
From equations 44 and 45 a complete description of the system is obtained. If [L]total 
>>[P]total we will have that [L]total ≈ [L] from equation 45, equation 44 can be then analysed 
with this approximation. With this first rough estimate of Ka, equation 45 can be solved for 
the [L] value for each [L]total. These values can be used in equation 44 to obtain an improved 
estimation of Ka, and this process should be repeated until the solution for Ka reaches a 
constant value. Equation 44 can be solved graphically using any of the plots presented in 
section 3.1. 
4.3.2 Fluorescence 
Fluorescence spectroscopy is a widely used tool in biochemistry due to its ease, sensitivity to 
local environmental changes and ability to describe target-ligand interactions qualitatively and 
quantitatively in equilibrium conditions. In this technique the fluorophore molecule senses 
changes in its local environment. To analyse ligand-target interactions it is possible to take 
advantage of the nature of ligands, excepcionally we can find molecules which are essentially 
non or weakely fluorescent in solution but show intense fluorescence upon binding to their 
targets (that is the case, for example, of colchicines and some of its analogues). Fluorescence 
moieties such as fluorescein can be also attached to naturally non-fluorescent ligands to make 
used of these methods. The fluorescent dye may influence the binding, so an essential control 
with any tagged molecule is a competition experiment with the untagged molecule.  Finally, in 
a few favourable cases the intrinsic tryptophan fluorescence of a protein changes when a 
ligand binds, usually decreasing (fluorescence quenching). Again, increasing concentrations of 
ligand to a fixed concentration of target (or vice versa) are incubated at controlled temperature 
and fluorescence changes measured until saturation is reached. Binding constant can be 
determined by fitting data according to equation 11 (Scatchard plot). From fluorescence data 
(F), υ can be calculated from the relantionship: 
  υ = Fmax- F
Fmax
 (46) 
If free ligand has an appreciable fluorescence as compared to ligand bound to its target, then 
the fluorescence enhancement factor (Q) should be determined. Q is defined as (Mas & 
Colman 1985): 
 Q = Fbound
Ffree
- 1 (47) 
To determine it, a reverse titration should be done. The enhancement factor can be obtained 
from the intercept of linear plot of 1/((F/F0)-1) against 1/P, where F and F0 are the observed 
fluorescence in the presence and absence of target, respectively. Once it is known, the 
concentration of complex can be determine from a fluorescence titration experiment using: 
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 [PL] = [L]total
(F/F0)	-	1
Q	-	1  (48) 
Thus the binding constant can be determined from the Scatchard plot as described above. 
4.3.3 Fluorescence anisotropy 
Fluorescence anisotropy measures the rotational diffusion of a molecule. The effective size 
of a ligand bound to its target usually increases enormously, thus restricting its motion 
considerably. Changes in anisotropy are proportional to the fraction of ligand bound to its 
target. Using suitable polarizers at both sides of the sample cuvette, this property can be 
measured. In a tritation experiment similar to the ones described above, the fraction of 
ligand bound (XL=[PL]/[L]total) is determined from:  
 XL=
r - r0
rmax - r0
 (49) 
where r is the anisotropy of ligand in the presence of the target molecule, r0 is the anisotropy 
of ligand in the absence of target and rmax is the anisotropy of ligand fully bound to its target 
(note that equation 49 can be used only in the case where ligand fluorescence intensity does 
not change, otherwise appropriate corrections should be done, see (Lakowicz 1999)). [P] can 
be calculated from: 
 [P] = [P]total - XL[L]total (50) 
The binding constant can be determined from the hyperbola: 
 XL	= Ka[P]1	+	Ka[P] (51) 
4.4 Competition methods 
The characterization of a ligand binding let us determine the binding constant of any other 
ligand competing for the same binding site. Measurements of ligand (L), target (P), reference 
ligand (R) and both complexes (PR and PL) concentrations in the equilibrium permit the 
calculation of the binding constant (KL) from equation 53 (see below) as the binding constant 
of the reference ligand (KR) is already known. 
 L + R + P ↔ PL + PR (52) 
 KL= KR
[PL][R][L][PR] (53) 
In the case that the reference ligand has been characterized due to the change of a ligand 
physical property (i.e. fluorescence, absorbance, anisotropy) upon binding, would permit us 
also following the displacement of this reference ligand from its site by competition with a 
ligand „blind“ to this signal (Diaz & Buey 2007). In this kind of experiment equimolar 
concentrations of the reference ligand and the target molecule are incubated, increasing 
concentrations of the problem ligand added and the appropiate signal measured. It is 
possible then to determine the concentration of ligand at which half the reference ligand is 
bound to its site (EC50). Thus KL is calculated from:  
 KL= 
1	+	[R]KR
EC50
 (54) 
 
Thermodynamics as a Tool for the Optimization of Drug Binding 777 
5. Drug optimization 
Microtubule stabilizing agents (MSA) comprise a class of drugs that bind to microtubules 
and stabilize them against disassembly. During the last years, several of these compounds 
have been approved as anticancer agents or submitted to clinical trials. That is the case of 
taxanes (paclitaxel, docetaxel) or epothilones (ixabepilone) as well as discodermolide 
(reviewed in (Zhao et al. 2009)). Nevertheless, anticancer chemotherapy has still 
unsatisfactory clinical results, being one of the major reasons for it the development of drug 
resistance in treated patients (Kavallaris 2010). Thus one interesting issue in this field is drug 
optimization with the aim of improving the potential for their use in clinics: minimizing 
side-effects, overcoming resistances or enhancing their potency. 
Our group has studied the influence of different chemical modifications on taxane and 
epothilone scaffolds in their binding affinities and the consequently modifications in ligand 
properties like citotoxicity. The results from these studies firmly suggest thermodynamic 
parameters as key clues for drug optimization. 
5.1 Epothilones 
Epothilones are one of the most promising natural products discovered with paclitaxel-like 
activity. Their advantages come from the fact that they can be produced in large amounts by 
fermentation (epothilones are secondary metabolites from the myxobacterium Sorangiun 
celulosum), their higher solubility in water, their simplicity in molecular architecture which 
makes possible their total synthesis and production of many analogs, and their effectiveness 
against multi-drug resistant cells due to they are worse substrates for P-glycoprotein. 
The structure affinity-relationship of a group of chemically modified epothilones was 
studied. Epothilones derivatives with several modifications in positions C12 and C13 and 
the side chain in C15 were used in this work. 
 
 
Fig. 1. Epothilone atom numbering. 
Epothilone binding affinities to microtubules were measured by displacement of Flutax-2, a 
fluorescent taxoid probe (fluorescein tagged paclitaxel). Both epothilones A and B binding 
constants were determined by direct sedimentation which further validates Flutax-2 
displacement method. 
All compounds studied are related by a series of single group modifications. The 
measurement of the binding affinity of such a series can be a good approximation of the 
incremental binding energy provided by each group. Binding free energies are easily 
calculated from binding constants applying equation 29. The incremental free energies (ΔG0) 
change associated with the modification of ligand L into ligand S is defined as: 
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 ΔΔG0(L→S) = ΔG0(L) – ΔG0(S) (55) 
These incremental binding energies were calculated for a collection of 20 different 
epothilones as reported in (Buey et al. 2004). 
 
Site Modification Compounds ΔΔG 
C15 S → R 4 → 17 ~ 27 
  7 → 18 ~ 27 
  14 → 16 17.8 ± 0.3 
 Thiazole → Pyridine 5 → 7 -2.9 ± 0.2 
  6 → 8 -2.1 ± 0.3 
  14 → 4 -0.2 ± 0.4 
  16 → 17 ~ 9.4 
C21 Methyl → Thiomethyl 2 → 3 -2.8 ± 0.8 
  5 → 10 -5.9 ± 0.6 
  6 → 11 -3.6 ± 0.3 
  8 → 12 2.6 ± 0.3 
 Methyl → Hydroxymethyl 8 → 9 1.4 ± 0.3 
 5-Thiomethyl-pyridine → 6-Thiomethyl-pyridine 12 → 13 4.1 ± 0.5 
C12 S → R 4 → 7 -2.1 ± 0.3 
  14 → 5 0.6 ± 0.3 
  17 → 18 ~ -2 
  19 → 11 9.0 ± 0.6 
  20 → 8 1.9 ± 0.4 
 Epoxide → Cyclopropyl 1 → 14 -4.7 ± 0.4 
  3 → 19 -5.4 ± 0.8 
 Cyclopropyl → Cyclobutyl 5 → 15 4.1 ± 0.2 
 S H → Methyl 1 → 2 -8.1 ± 0.6 
  4 → 20 -1.8 ± 0.5 
 R H → Methyl 5 → 6 0.4 ± 0.3 
  7 → 8 1.2 ± 0.2 
  10 → 11 2.7 ± 0.7 
Table 1. Incremental binding energies of epothilone analogs to microtubules. (ΔΔG in 
kJ/mol at 35ºC). Data from (Buey et al. 2004).  
The data in table 1 show that the incremental binding free energy changes of single 
modifications give a good estimation of the binding energy provided by each group. 
Moreover, the effect of the modifications is accumulative, resulting the epothilone derivative 
with the most favourable modifications (a thiomethyl group at C21 of the thiazole side 
chain, a methyl group at C12 in the S configuration, a pyridine side chain with C15 in the S 
configuration and a cyclopropyl moiety between C12 and C13) the one with the highest 
affinity of all the compounds studied (Ka 2.1±0.4 x 1010 M-1 at 35ºC). 
The study of these compounds showed also a correlation between their citotoxic potencial 
and their affinities to microtubules. The plot of log IC50 in human ovarian carcinoma cells 
versus log Ka shows a good correlation (figure 2), suggesting binding affinity as an 
important parameter affecting citotoxicity.  
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Fig. 2. Dependence of the IC50 of epothilone analogs against 1A9 cells on their Ka to 
microtubules. Data from (Buey et al. 2004). 
5.2 Taxanes 
Paclitaxel and docetaxel are widely used in the clinics for the treatment of several carcinoma 
and Kaposi’s sarcoma. Nevertheless, their effectiveness is limited due to the development of 
resistance, beeing its main cause the overexpression and drug efflux activity of 
transmembrane proteins like P-glycoprotein (Shabbits et al. 2001). 
We have studied the thermodynamics of binding of a set of nearly 50 taxanes to crosslinked 
stabilized microtubules with the aim to quantify the contributions of single modifications at 
four different locations of the taxane scaffold (C2, C13, C7 and C10). 
 
 
Fig. 3. Taxanes head compounds. Atom numbering 
Once confirmed that all the compounds were paclitaxel-like MSA, their affinities were 
measured using the same competition method mentioned above (section 5.1. displacement 
of Flutax-2). Seven of the compounds completely displaced Flutax-2 at equimolar 
concentrations indicating that they have very high affinities and so they are in the limit of 
the range to be accurately calculated by this method (Diaz&Buey 2007). The affinities of 
these compounds were then measured using a direct competition experiment with 
epothilone-B, a higher-affinity ligand (Ka 75.0 x 107 at 35ºC compared with 3.0 x 107 for 
Flutax-2). With all the binding constants determined at a given temperature, it is possible to 
determine the changes in binding free energy caused by every single modification as 
discussed above for epothilones (table 2). 
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Site Modification Compounds ΔΔG Average 
C2 benzoyl → benzylether T → 25 13.2 +13.0 ± 0.2 
  21 → 24 12.8  
 benzoyl → benzylsulphur T → 27 13.6 +15.9 ± 2.3 
  21 → 26 18.1  
 benzoyl → benzylamine T → 38 18.6 +20.1 ± 1.5 
  21 → 39 21.6  
 benzoyl → thiobenzoyl T → 23 19.6 +15.9 ± 3.8 
  21 → 22 12.1  
 benzoyl → benzamide 21 → 42 19.2  
 benzamide → 3-methoxy-benzamide 42 → 43 -3.4  
 benzamide → 3-Cl-benzamide 42 → 44 5.3  
 benzoyl → 3 methyl- 2 butenoyl 1 → 2 6.2  
 benzoyl → 3 methyl- 3 butenoyl 1 → 3 4.9  
 benzoyl → 2(E)-butenoyl 1 → 9 7.3  
 benzoyl → 3 methyl- butanoyl 1 → 10 6.3  
 benzoyl → 2-debenzoyl-1,2-carbonate C → 16 5.8  
 benzoyl → 3-azido-benzoyl 1 → 4 -8 -11.2 ± 1.3 
  T → 12 -13.9  
  C → 14 -12.2  
  18 → 20 -10.6  
 benzoyl → 3-methoxy-benzoyl 1 → 5 -6.2 -7.2 ± 0.6 
  T → 11 -8.3  
  C → 13 -8.1  
  18 → 19 -6.3  
 benzoyl → 3-Cl-benzoyl 1 → 6 -3.1  
 benzoyl → 3-Br-benzoyl 1 → 34 -2.3  
 benzoyl → 3-I-benzoyl 1 → 30 -3.3  
 benzoyl → 3-ciano-benzoyl 1 → 7 0.6  
 benzoyl → 3-methyl-benzoyl 1 → 8 0  
 benzoyl → 3-hydroxymethyl-benzoyl 1 → 36 7.2  
 benzoyl → 3-hydroxy-benzoyl 18 → 37 9.2  
 3-Cl-benzoyl → 2,4-di-Cl-benzoyl 6 → 29 4.8  
 benzoyl → 2,4-di-F-benzoyl 1 → 28 2.7  
 3-methoxy-benzoyl → 2,5-di-methoxy-benzoyl 5 → 35 4.6  
 benzoyl → 2-thienoyl 1 → 31 4.1  
 benzoyl → 3-thienoyl 1 → 32 1.8  
 benzoyl → 6-carboxy-pyran-2-one 1 → 41 8.1  
C13 paclitaxel → cephalomannine T → C 1.9 +2.0 ± 0.2 
  11 → 13 1.9  
  12 → 14 1.6  
  15 → 17 2.4  
 paclitaxel → docetaxel 23 → 22 -1.7 -3.2 ± 0.9 
  25 → 24 -6.2  
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  27 → 26 -1.3  
  38 → 39 -2.8  
  T → 21 -4.2  
 cephalomannine → docetaxel C → 21 -3.8 -5.6 ± 1.1 
  17 → D -7.7  
  20 → 40 -5.2  
C10 acetyl → hydroxyl T → 15 -1.3 -1.7 ± 0.8 
  C → 17 -0.7  
  21 → D -3.2  
 propionyl → hydroxyl 18 → 17 0.9  
 acetyl → propionyl C → 18 -1.6 -0.5 ± 0.4 
  13 → 19 0.2  
  14 → 20 0  
C7 propionyl → hydroxyl 17 → 1 -1.6  
Table 2. Incremental binding energies of taxane analogs to microtubules. (ΔΔG in kJ/mol at 
35ºC). Data from (Matesanz et al. 2008). 
In this way, it is possible to select the most favourable substituents at the positions studied 
and design optimized taxanes. According to the data obtained, the optimal taxane should 
have the docetaxel side chain at C13, a 3-N3-benzoyl at C2, a propionyl at C10, and a 
hydroxyl at C7. From compound 1 with a binding energy of -39.4 kJ/mol, the modifications 
selected would increase the binding affinity in -5.6 kJ/mol from the change of the 
cephalomannine side chain at C13 to the docetaxel one, -11.2 kJ/mol from the introduction 
of 3-N3-benzoyl instead of benzoyl at C2, -1.6 kJ/mol from the substitution of a propionyl at 
C7 with a hydroxyl, and -0.9 kJ/mol from the change of a hydroxyl at C10 to a propionyl. 
Thus, this optimal taxane would have a predicted ΔG at 35ºC of -58.7 kJ/mol. This molecule 
was synthesized (compound 40) and its binding affinity measured using the epothilone-B 
displacement method and the value obtained is in good corespondence with the predicted 
one: Ka = 6.28±0.15 x 109 M-1; ΔG = -57.7±0.1 kJ/mol (Matesanz et al. 2008). This value means 
a 500-fold increment over the paclitaxel affinity. 
It is also possible to check the influence of the modifications on the cytotoxic activity 
determining the IC50 of each compound in the human ovarian carcinoma cells A2780  and 
their MDR counterparts (A2780AD). The plots of log IC50 versus log Ka (figure 4) indicate 
that, as in the case of epothilones, both magnitudes are related, and the binding affinity acts 
as a good predictor of citotoxicity. In this type of MDR cells the high-affinity drugs are circa 
100-fold more cytotoxic than the clinically used taxanes (paclitaxel and docetaxel) and 
exhibit very low resistance indexes. 
The plot of log resistance index against log Ka shows a bell-shaped curve (figure 5). 
Resistance index present a maximum for taxanes with similar affinities for microtubules and 
P-glycoprotein, then rapidly decreases when the affinity for microtubules either increases or 
decreases. To find an explanation for this behaviour we should note that the intracellular 
free concentration of the high-affinity compounds will be low. To be pumped out by P-
glycoprotein ligands must first bind it, so ligand outflow will decrease with lower free 
ligand concentrations (discussed in (Matesanz et al. 2008)). In the case of the low-affinity 
drugs, the concentrations needed to exert their citotoxicity are so high that the pump gets 
saturated and cannot effectively reduced the intracellular free ligand concentration. 
 
Thermodynamics – Interaction Studies – Solids, Liquids and Gases 782 
 
Fig. 4. Dependence of the IC50 of taxane analogs against A2780 non-resistant cells (black 
circles, solid line) and A2780AD resistant cells (white circles, dashed line) on their Ka to 
microtubules. Data from (Matesanz et al. 2008).  
 
 
Fig. 5. Dependence of the resistance index of the A2780AD MDR cells on the Ka of the 
taxanes to microtubules. Data from (Yang et al. 2007; Matesanz et al. 2008). 
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6. Conclusion 
We found a correlation between binding affinities of paclitaxel-like MSA to microtubules 
and their citotoxicities in tumoral cells both MDR and non-resistant. The results with 
taxanes further validate the binding affinity approach as a tool to be used in drug 
optimization as it was previously discuss for the case of epothilones. Moreover, from the 
thermodynamic data we could design novel high-affinity taxanes with the ability to 
overcome resistance in P-glycoprotein overexpressing cells. Anyway, there is a limit 
concentration below which MSA are not able to kill cells (discussed in (Matesanz et al. 
2008)), the highest-affinity compounds studied have no dramatically better citotoxicities 
than paclitaxel or docetaxel have. Thus, the goal is not to find the drug with the highest 
cytotoxicity possible but rather to find one able to overcome resistances. The study of 
taxanes indicates that increased drug affinity could be an improvement in this direction. The 
extreme example of that come from the covalent binding of cyclostreptin (Buey et al. 2007) 
(that might be consider as infinite affinity) having a resistance index close to one.  
However, in the case of chemically diverse paclitaxel-like MSA, the inhibition of cell 
proliferation correlates better with enthalpy change than with binding constants (Buey et al. 
2005) suggesting that favourable enthalpic contributions to the binding are important to 
improve drug activity as it has been shown for statins and HIV protease inhibitors (Freire 
2008). 
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